GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (LTS:0UGB) » Definitions » EV-to-FCF

Cosciens Biopharma (LTS:0UGB) EV-to-FCF : 0.68 (As of Dec. 13, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cosciens Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cosciens Biopharma's Enterprise Value is C$-13.22 Mil. Cosciens Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-19.31 Mil. Therefore, Cosciens Biopharma's EV-to-FCF for today is 0.68.

The historical rank and industry rank for Cosciens Biopharma's EV-to-FCF or its related term are showing as below:

LTS:0UGB' s EV-to-FCF Range Over the Past 10 Years
Min: -2087.7   Med: -2.21   Max: 289.62
Current: 0.68

During the past 13 years, the highest EV-to-FCF of Cosciens Biopharma was 289.62. The lowest was -2087.70. And the median was -2.21.

LTS:0UGB's EV-to-FCF is ranked better than
71.06% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs LTS:0UGB: 0.68

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Cosciens Biopharma's stock price is C$4.13. Cosciens Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-5.408. Therefore, Cosciens Biopharma's PE Ratio (TTM) for today is At Loss.


Cosciens Biopharma EV-to-FCF Historical Data

The historical data trend for Cosciens Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma EV-to-FCF Chart

Cosciens Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.79 12.67 15.02 5.59 -1.76

Cosciens Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.27 -1.76 -2.11 2.03 0.48

Competitive Comparison of Cosciens Biopharma's EV-to-FCF

For the Biotechnology subindustry, Cosciens Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's EV-to-FCF falls into.



Cosciens Biopharma EV-to-FCF Calculation

Cosciens Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-13.221/-19.306
=0.68

Cosciens Biopharma's current Enterprise Value is C$-13.22 Mil.
Cosciens Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-19.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (LTS:0UGB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cosciens Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.13/-5.408
=At Loss

Cosciens Biopharma's share price for today is C$4.13.
Cosciens Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-5.408.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cosciens Biopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

Cosciens Biopharma Headlines

No Headlines